^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PGR (Progesterone receptor)

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    23h
    FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (clinicaltrials.gov)
    P2, N=99, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative • PGR positive
    1d
    DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=96, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2028 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    1d
    Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date • Checkpoint inhibition • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • decitabine
    1d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    1d
    Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis (clinicaltrials.gov)
    P2, N=6, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Nov 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab)
    1d
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Not yet recruiting, West German Study Group | N=1050 --> 1520
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • Orserdu (elacestrant)
    1d
    Surgical debulking with fertility preservation in primary extra-neural ependymoma presenting with widespread peritoneal and intra-abdominal disease: Case report and literature review. (PubMed, Gynecol Oncol Rep)
    Given limited evidence, optimal management remains undefined however surgical cytoreduction continues to be the cornerstone of management across reported cases with adjuvant treatment individualised. Certain fertility preservation strategies are concurrently feasible within a multidisciplinary framework and should be considered given reported cases are predominantly seen in younger females.
    Journal
    |
    PGR (Progesterone receptor) • MUC16 (Mucin 16, Cell Surface Associated)
    1d
    A rare case of multifocal vulvar carcinoma of mammary gland type (AMGT) with mucinous features: Differential diagnosis and literature review. (PubMed, Gynecol Oncol Rep)
    Immunohistochemistry is critical in identifying the "mammary-like" phenotype of AMGT and excluding other primary and metastatic tumors of vulva. The unique biologic profile of AMGT dictates a treatment strategy distinct from other primary vulvar tumors.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • GATA3 (GATA binding protein 3)
    1d
    Pure Mucinous Breast Carcinoma: Integrating Molecular and Immunohistochemical Profiles for Accurate Diagnosis-A Case Report. (PubMed, Case Rep Oncol Med)
    Pure MCB is a rare, low-grade tumor with distinct pathological features. Accurate diagnosis and complete surgical excision are essential for optimal management, as patients typically achieve excellent long-term outcomes.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + AR positive + ER positive
    2d
    Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKang (dalpiciclib)
    2d
    Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, The Methodist Hospital Research Institute | N=39 --> 51 | Trial completion date: Dec 2025 --> Dec 2028
    Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • PD-L1 negative
    |
    BluePrint
    |
    Herceptin (trastuzumab) • Imfinzi (durvalumab) • Perjeta (pertuzumab)
    3d
    Breast MRI biomarkers of tumor biology: integrating imaging with pathology to guide clinical care. (PubMed, Eur J Radiol)
    Standardized BI-RADS breast MRI descriptors demonstrate consistent and independent associations with established pathological biomarkers and molecular subtypes. Although MRI does not replace tissue-based assessment, these imaging phenotypes may provide complementary biological context and support radiopathological correlation in multidisciplinary care. Given the retrospective, single-center design with single-reader assessment and absence of external validation, these findings should be interpreted with appropriate caution and require prospective multicenter confirmation before clinical implementation.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive